PUF Agraflora Organics International

AgraFlora Announces Farmako Supply Agreement of Proprietary THC Testkits to STADAPHARM

AgraFlora Announces Farmako Supply Agreement of Proprietary THC Testkits to STADAPHARM

Wholly-Owned German Subsidiary Developed THC Testkits In-House to Help Pharmacists Identify Medical Cannabis

VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- (“AgraFlora” or the “Company”) (CSE: ) (Frankfurt: ) (OTCPK: is pleased to announce that its wholly-owned subsidiary, Farmako GmbH (“Farmako”) – a GDP certified pharmaceutical wholesaler with a focus on the cannabinoid therapy – has begun supplying STADAPHARM GmbH (“STADAPHARM”) with its proprietary THC Testkits (the “THC Testkits”). The THC Testkits were developed and produced by Farmako in-house and will be supplied to STADAPHARM as a tool for pharmacists to detect THC and identify medical cannabis flowers and extracts in an easy, quick and cost-efficient way.

STADAPHARM, which is responsible for the Specialty Pharmaceuticals business within the STADA Group, will be entering the medical cannabis market in the second quarter of 2021. The company will launch its own THC-containing cannabis flower products and extracts and will also offer the THC Testkits, developed and produced by Farmako, along with its own products to pharmacists for the identity testing of medical cannabis.

“Katrin and everyone at Farmako continue to demonstrate their ingenuity and passion for the cannabis industry in Germany. I am very proud of the team and commend their efforts to develop the THC Testkit in-house, obtain patent protection, bring it to market and secure the supply agreement with STADAPHARM,” said Elise Coppens, Chief Executive Officer and Director of AgraFlora.

“Discussion in the German cannabis market often circles around the high barriers for patients, suppliers, doctors and pharmacists. Therefore, we as Farmako want to facilitate easier access to cannabinoid therapy for patients with a high burden of suffering via fair prices, reliable supply and efficient service for healthcare professionals. For us, cooperation is an important element of competition, only in this way can we develop the market for the benefit of patients. Therefore, we are very happy about this partnership with STADAPHARM, a highly renowned pharma corporation,” commented Katrin Eckmans, CEO of Farmako GmbH.

Farmako has been supplying THC Testkits to pharmacies since December 2020. The THC Testkit, for which Farmako holds patent protection, facilitates identity testing of cannabis in only five minutes, without the need for further auxiliary devices or expensive reference substances – thus offering a better alternative to the time-consuming and costly thin layer chromatography method of identity testing pharmaceutical ingredients or medicines containing THC. Further, the THC Testkit has been validated by the German testing laboratory DSI-pharm, Quality Services International GmbH, regarding its specificity for the purpose of identifying cannabis flowers and extracts according to German Pharmacopoeia.

Farmako has been active as reliable supplier of medical cannabis flowers since beginning of 2019. In Q4 2020 the product portfolio was enhanced by pharma-grade CBD isolate (GMP) as well as the THC TestKit and IMC cannabis flowers. In the second quarter of 2021, Farmako will further complement its product range by offering its own high THC cannabis extracts at a fair price. In this way, Farmako takes root as a supplier with a comprehensive portfolio in the medical cannabis market and continues to present itself as reliable partner for the retail and wholesale market.

About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a leading cannabis company building shareholder value through the development of revenue generating operating assets in the global cannabis industry. AgraFlora is focused primarily on the Canadian cannabis industry – the world’s most advanced and regulated legal cannabis market. Its flagship Canadian asset is Propagation Services Canada, a large-scale commercial greenhouse in Delta, BC focused on reshaping the Canadian flower market with high-potency, low-cost cannabis. In addition, AgraFlora’s wholly-owned subsidiary, Farmako GmbH, is focused on becoming Europe’s leading distributor of medical cannabis. Farmako currently has active distribution operations in Germany and expects to commence active operations in the United Kingdom in 2021. For more information about AgraFlora, please visit and its profile page on SEDAR at .

ON BEHALF OF THE BOARD OF DIRECTORS

Nick Kuzyk, Investor Relations

E:

T: (800) 783-6056

For French inquiries:

Maricom Inc.        

Remy Scalabrini                                                

E:

T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan” “expect” “project” “intend” “believe” “anticipate” “estimate” and other similar words or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including but not limited to delays or uncertainties with regulatory approvals including that of the CSE. There are uncertainties inherent in forward-looking information including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators which are available at



EN
12/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agraflora Organics International

 PRESS RELEASE

CSE Bulletin: Name Change - AgraFlora Organics International Inc. (AGR...

Toronto, Ontario--(Newsfile Corp. - le 26 juillet/July 2021) AgraFlora Organics International Inc. has announced a name change to Agra Ventures Ltd. Shares will begin trading under the new name and with a new CUSIP number on July 28, 2021. The symbol will remain the same. Disclosure documents are available at www.thecse.com Please note that all open orders will be cancelled at the end of business on July 27, 2021. Dealers are reminded to re-enter their orders. _________________________________ AgraFlora Organic...

 PRESS RELEASE

AgraFlora Organics International Inc. Changing Name to Agra Ventures L...

AgraFlora Organics International Inc. Changing Name to Agra Ventures Ltd. Propagation Services Canada Subsidiary Also Re-Branded As Boundary Bay Cannabis to Coincide with the First Cannabis Crop Harvest VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- (“AGRA” or the “Company”) (CSE: ) (Frankfurt: ) (OTCPK: is pleased to announce that effective July 28, 2021, it will change its name (the ‘Name Change”) to Agra Ventures Ltd. (“Agra Ventures”) to better reflect the evolved vision and strategic direction of the Company under current leadership. The Canadian Securities Exchan...

 PRESS RELEASE

AgraFlora Announces Debt Settlement

AgraFlora Announces Debt Settlement VANCOUVER, British Columbia, July 19, 2021 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) announces that its Board of Directors has approved the settlement of amounts owing for services rendered (the "Debt Settlement") through the issuance of common shares (the “Shares”). Pursuant to the Debt Settlement, the Company issued an aggregate amount of 803,783 Shares at a deemed price of $0.05 per Share. All Shares issued will be subject to a minimum hold period of four mont...

 PRESS RELEASE

AgraFlora Appoints Fiona Fitzmaurice as its New Chief Financial Office...

AgraFlora Appoints Fiona Fitzmaurice as its New Chief Financial Officer Former CFO Amicably Departing the Company to Facilitate the Transition VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- (“AgraFlora” or the “Company”) (CSE: ) (Frankfurt: ) (OTCPK: is pleased to announce that Fiona Fitzmaurice has been appointed as AgraFlora’s new Chief Financial Officer (“CFO”) effective May 1, 2021, subject to the final acceptance of the Canadian Securities Exchange (the “CSE”). Ms. Fitzmaurice is a Chartered Professional Accountant with over 14 years of experience in accounting and...

 PRESS RELEASE

AgraFlora Announces Farmako Supply Agreement of Proprietary THC Testki...

AgraFlora Announces Farmako Supply Agreement of Proprietary THC Testkits to STADAPHARM Wholly-Owned German Subsidiary Developed THC Testkits In-House to Help Pharmacists Identify Medical Cannabis VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- (“AgraFlora” or the “Company”) (CSE: ) (Frankfurt: ) (OTCPK: is pleased to announce that its wholly-owned subsidiary, Farmako GmbH (“Farmako”) – a GDP certified pharmaceutical wholesaler with a focus on the cannabinoid therapy – has begun supplying STADAPHARM GmbH (“STADAPHARM”) with its proprietary THC Testkits (the “THC Testkit...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch